By ARTES Biotechnology…
To get in touch with ARTES Biotechnology and Boehringer Ingelheim Animal Health Announce Collaboration, simply fill out the form below.
Subscribe to Supplier
ARTES Biotechnology and Boehringer Ingelheim Animal Health Announce Collaboration
Langenfeld, Germany: – ARTES Biotechnology specialized in recombinant protein production, process and vaccine development from microbial expression systems announces a collaboration with the global pharmaceutical company Boehringer Ingelheim Animal Health.
ARTES’ expression system Hansenula polymorpha is the preferred technology for affordable mass vaccination and recommended by the World Health Organization (WHO) for these purposes. In combination with ARTES’ METAVAX® platform, this offers a new, unique and very economical approach to low-cost mass production of safe and effective vaccines required in the veterinary field.
“This collaboration is another milestone in expanding our vaccine development expertise”, Michael Piontek, managing director of ARTES stated. “We are more than confident that our technology platform is perfectly suited for the development of safe and cost efficient vaccines that are highly relevant for the veterinary market.”
“Partnering is a central part of our strategy. We are excited about this collaboration and the opportunity to develop more innovative vaccines for the animal health market,” says Rolf-Dieter Günther, Head of Global Business Development and Licensing Animal Health for Boehringer Ingelheim.
About ARTES Biotechnology
ARTES Biotechnology is a pharmaceutical contract research organization (CRO) that provides cell line and process development for bio-pharmaceutical products. The company is a well-established partner for many of the biggest names in the industry, with more than 20 years of business experience, a track record of products developed for and marketed by clients as well as safe, reliable and highly competitive microbial production platforms.
ARTES markets unique virus-like particle (VLP) technology for vaccine developments triggering humoral and cellular immune answers. The VLP technology is applicable for large and multimeric antigens derived from a large variety of pathogens.
The CRO based in Langenfeld, Germany, also supports product development with contributions that include:
- Cell line engineering based on yeast (Hansenula polymorpha) and bacterial (E. coli and Bacillus) expression platforms
- VLP based antigen presentation
- Lab scale up- and downstream process development
- Supply of non-GMP bulk material (API) for activity and toxicity tests
- Technology transfer to cGMP facilities and scale-up support